Nicotinamide and phosphate homeostasis in chronic kidney dis... : Current Opinion in
Nephrology and Hypertension Nicotinamide and phosphate homeostasis in chronic kidney …

Hyperphosphatemia in chronic kidney disease (CKD) has been associated with elevated
cardiovascular morbidity and mortality. Serum phosphate control remains a cornerstone of …

Phosphate binders have traditionally been used to treat hyperphosphatemia, a common
complication in patients with end stage renal disease (ESRD). New evidence suggests that …

Hyperphosphatemia is an important modifiable risk factor for death and cardiovascular
events in patients on hemodialysis (HD). As nicotinamide has been shown as an inhibitor of …

Background: Studies indicate that nicotinic acid and related compounds may decrease
phosphorus concentrations effectively by reducing the absorption in the gastrointestinal …

Background: Hyperphosphatemia is common in hemodialysis patients. Recent animal
studies show that nicotinamide inhibits the sodium dependent phosphate co-transport in the …

Background: Recent evidence has shown that nicotinamide treatment may have an impact
on phosphorus metabolism in hemodialysis patients. Nevertheless, the treatment remains …

Background: Nicotinamide (NAM) has been proposed as an alternative treatment to
phosphate binders for hyperphosphataemia in chronic kidney disease. Methods: The …

Background Hyperphosphatemia is commonly found in dialysis patients, which can lead to
fatal cardiovascular diseases. The objective of this study was to evaluate the effectiveness …

Background Hyperphosphatemia is a common problem in patients with end-stage renal
disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the …